Petros Pharmaceuticals, Inc. (PTPI): auditor change — Petros Pharmaceuticals dismisses CBIZ CPAs, appoints HTL International as auditor

Petros Pharmaceuticals, Inc.

Audit Committee approved dismissal of CBIZ CPAs as auditor effective Aug 29, 2025.
CBIZ CPAs had been engaged on April 5, 2025 after acquiring Marcum's attest business.
No disagreements with CBIZ CPAs; only reportable event was previously disclosed material weakness in internal controls.
Engaged HTL International as new independent auditor for fiscal year ending Dec 31, 2025, effective Aug 29.
No prior consultations with HTL regarding accounting or auditing matters.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Petros Pharmaceuticals, Inc. dismissed CBIZ CPAs P.C. as its auditor.

Action: dismissal
Auditor: CBIZ CPAs P.C.

Exact text from the filing

On August 29, 2025, the Audit Committee of the Board of Directors (the “Committee”) of Petros Pharmaceuticals, Inc. (the “Company”) approved the dismissal of CBIZ CPAs P.C. (“CBIZ CPAs”) as the Company’s independent registered public accounting firm, effective as of the same date.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Petros Pharmaceuticals, Inc. engaged HTL International, LLC as its auditor.

Action: engagement
Auditor: HTL International, LLC

Exact text from the filing

On August 29, 2025, the Committee engaged HTL International, LLC (“HTL”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, effective immediately.

View on SEC.gov

Browse all auditor changes →

Petros Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-087887

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.